Funded project
Remedium Bio - Gene Therapy for Regenerative Medicine

Remedium Bio - Gene Therapy for Regenerative Medicine

Type 2 Diabetes
Remedium Bio is a regenerative medicine biotechnology company, that has developed the only dose-adjustable gene therapy platform technology Prometheus™ and is currently advancing multiple assets with uncorrelated risk to Investigational New Drug (IND) approval.
75.61% Voted Yes
Remedium Website
Frank Luppino
CEO & Founder
Alex Goraltchouk
Alexey Seregin
Vice President, R&D

Preclinical and IND enabling studies

Gene therapy platform


Patent Status
Multiple patents and more pending applications



Remedium Biotechnologies is a regenerative medicine biotech company focused on addressing age-related diseases and significant unmet clinical needs. A key problem in this field is the inefficiency of current treatments for conditions like Osteoarthritis (OA), Type 2 Diabetes (T2D), and obesity. For instance, OA treatments are limited by the pharmacokinetics of the joints, requiring frequent FGF18 protein injections, while protein-based treatments for T2D and obesity suffer from pharmacokinetic sawtoothing, leading to safety and efficacy concerns. Gene therapy offers a potential solution but is hindered by high costs, inflexibility in dosage adjustments post-administration, and the inability to discontinue treatment if needed.

Aims and Progress to Date

Remedium aims to revolutionize therapeutic protein delivery with its proprietary Prometheus™ gene delivery platform. This technology is designed for highly localized, durable expression of therapeutic genes, offering adjustable dosing capabilities and avoiding the limitations of current gene therapy methods. Remedium's lead candidate, RMD1101, is a pioneering regenerative treatment for OA, delivering the FGF18 transgene to arthritic joints. This treatment has demonstrated significant efficacy in preclinical models, showing dose-dependent increases in cartilage thickness and improved safety profiles. Additionally, their RMD1202 treatment for obesity and T2D has shown promising results in preclinical models, matching the efficacy of daily incretin injections while potentially reducing side effects due to minimized pharmacokinetic spikes.


Remedium is progressing towards licensing its Prometheus™ platform to major pharmaceutical and biotech companies, anticipated in the first half of 2024. Additionally, two IND submissions are planned for Q1 and Q4 of 2025 on RMD compounds. Their platform is also being evaluated for a range of other applications, including treatments for diabetes, rheumatoid arthritis, atopic dermatitis, enzyme replacement therapies, and longevity enhancement.
Given the significant market opportunities in these areas, and the platform's potential to improve efficacy, reduce costs, and enhance patient tolerability, Remedium is well-positioned for substantial growth and impact in the regenerative medicine and biotech sectors in the coming years.

Series A Round
Required Funding: $15M
Duration: Ongoing

VitaDAO Board Evaluation Writeup

The Prometheus™ platform offers a cost-effective, adjustable gene therapy delivery for a range of treatments. Key products include RMD1101, a first-in-class regenerative therapy for Osteoarthritis leveraging the clinically validated FGF18 mechanism, and RMD1202, a novel single injection treatment for Type 2 Diabetes, poised to overcome the limitations of existing therapies. Backed by a seasoned leadership team with a history of successful therapy development and commercialization, Remedium is well-positioned in the biotech field. However, the company faces typical preclinical biotech risks including manufacturing, regulatory challenges, and market-driven financial uncertainties. To mitigate these risks, Remedium has employed strategies like utilizing multiple contract development and manufacturing organizations, extensive preclinical testing, leveraging clinically validated technological elements, a tiered intellectual property strategy, and efficient fund utilization through academic collaborations and strategic staffing.

Projects supported
No items found.

Latest Project Updates

No items found.
Project Initiated!

Discover more projects & initiatives

The Longevity Prize


The Longevity Prize is a series of prizes to award and accelerate progress in longevity and rejuvenation research. It was initiated by VitaDAO and funded through donations through our gitcoin quadratic donation round and partnered with Foresight Institute, Methuselah Foundation and Lifespan.

$ 24,000
View Project

The VitaDAO Longevity Fellowship


The VitaDAO Longevity Fellowship is aimed at distributing need-based micro grants to help students and early career stage individuals with interest in longevity get more deeply involved in longevity. This is aimed at activities ranging from short term research to attending a conference, or joining a program such as the Longevity Biotech Fellowship.

$ 20,000
View Project

Humanity - Proprietary Aging Score App


Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.

$ 50,000
View Project

Matrix Bio - Long-lived Species Inspired Longevity Biotech


VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rats to humans.

$ 300,000
View Project

Are you working on the next longevity science breakthrough?

Click here to explore the VitaDAO Project Funding FAQ.